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mate the impact of the new treatment on annual budgets
and health outcomes is shown. For chronic diseases, the
impact of a new treatment on annual budget and health
outcomes may change over the first few years, until a new
steady state is reached. How these estimates vary with
different assumptions about the extent of use of the new
treatment is shown. A method for generating these esti-
mates using a model developed to estimate the budget
and health outcome impacts of new HIV treatments for
state- or federally-funded programs is illustrated. Popula-
tion estimates allow healthcare decision-makers to evalu-
ate the impact on their budgets and patient health of 1)
providing the new treatment to their patients, and 2)
ensuring that they have sufficient funds available. This
workshop will be of value both to industry pharmaco-
economists and national and/or local healthcare decision-
makers. How to generate analyses of economic and health
outcomes in a population format that is likely to be of
value for new treatment decisions will be shown.
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Handling survival data in cost-effectiveness (CE) studies
generally implies an assessment of the survival data pre-
sented in clinical trials (measured survival), together with a
long-term prediction of life expectancy for the same pa-
tients (predicted survival). Because different methods are
needed to manage the data of measured survival and of
predicted survival, this workshop will present an overview
of these methods and discuss their relative advantages and
disadvantages. 1. Measured survival: When a single clini-
cal trial is the source of the survival information, tradi-
tional methods for constructing survival curves can be uti-
lized in CE studies. When two or more clinical trials are
available, combining the data requires a survival meta-
analysis. Although the methodology of survival meta-anal-
ysis is still under development, some techniques in this area
have adequately been tested and can therefore be proposed
for general use. 2. Predicted survival: Traditional life-
expectancy calculations remain the mainstay for predicting
survival in healthy subjects or in “cured” patients. Specific
methods, however, are needed for correcting normal life
expectancy predictions on the basis of the presence of a
disease condition. The Gompertz extrapolation technique
can be used for conditions where the chance of cure is min-
imal. Furthermore, other methods have recently been pro-
posed for combining the clinical evidence of a specific
survival pattern with the assignment of a normal life ex-
pectancy to “long term survivors.” This workshop is de-
signed to provide an overview of the foregoing methods; to
report on their use in clinical and economic evaluation;
and to present detailed examples of their application. It is
expected that workshop attendees will be primarily re-
searchers and analysts concerned with clinical and eco-
nomic evaluation, particularly where multi-center collabo-
ration is involved.
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Society’s perspective of costs and benefits of healthcare
programs has been well established in theory and method-
ology of outcomes research. Far less rigorously examined
are issues from the perspective of the payers. For rehabili-
tation programs in Germany, the perspective of Social Old
Age Insurance Funds (SOAIF) is of particular importance.
For the workforce, SOAIF finances most rehabilitative in-
terventions; they finance invalidity pensions in cases where
their insured can no longer participate in the workforce;
and rehabilitation programs are designed to avoid invalid-
ity. In the workshop, theoretical and methodological issues
of a payer’s perspective in general, and of SOAIF in partic-
ular, are discussed. Four perspectives of SOAIF can be dis-
tinguished: 1) minimizing SOAIF’s expenditure—this re-
quires financing rehabilitative intervention in case it can be
assumed that the expenditure for invalidity pensions saved
through an intervention exceeds the expenditure for the in-
tervention itself; 2) minimizing costs and cases of invalidity
according to the (German) social code on rehabilitation—
here the costs of interventions are not considered; 3) maxi-
mizing a social welfare function—as part of social insur-
ance and the welfare state arrangements, SOAIF could be
required to maximize a social welfare function, which
could be identical to society’s perspective; and 4) maximiz-
ing the utility function of SOAIF’s bureaucrats—according
to this perspective, as many rehabilitation interventions
will be produced as is necessary to maximize power, pres-
tige and income of the functionaries of the pension funds.
Consequences for study designs are discussed.
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Pharmacoeconomic and quality of life analyses are becom-
ing more familiar and hence more important to marketing
and reimbursement. The use of piggyback studies as an an-
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alytic technique has increased rapidly. A piggyback study
is performed alongside an existing clinical trial, leaving the
clinical components intact and undisturbed. Because clini-
cal safety and efficacy are the drivers behind the trial, ef-
forts are made to ensure that clinical endpoints are not
compromised by the economic substudy. This growing em-
phasis on cost-effectiveness and improvements in humanis-
tic attributes (QOL, ADLs, functioning) has caused many
researchers to add poor economic and quality of life sub-
studies in an attempt to tell compelling stories about their
products. PE/QOL studies should be developed with a
strong foundation. This workshop will provide a detailed
review of the fundamental steps necessary to properly de-
sign a piggyback study in the international setting. These
steps are: the development of a priori objectives and target
audience; hypotheses; endpoints to be measured; definition
of the target population; selection of appropriate compara-
tors; the time-frame to be analyzed; determination of how
the data shall be collected; creation of an analysis plan;
costing the data; data analysis; and, lastly, the reporting of
the results in a concise and meaningful way. Defining the
objectives and hypotheses will be the focus of the work-
shop, with a review of the other steps. This session is di-
rected at individuals in pharmaceutical firms, contract re-
search organizations (CROs), and consultant companies
who are responsible for the design and conduct of pharma-
coeconomic evaluations.
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This workshop offers a critical examination of the use of
patient self-reports in pharmacoeconomic evaluations. It is
directed at individuals in pharmaceutical firms, CROs, and
consultant companies who are responsible for the design
and conduct of pharmacoeconomic evaluations. This work-
shop advances current research by concentrating on how
the data collection method—in prospective clinical eco-
nomic evaluations—influences study results. Scant atten-
tion has been paid to the fact that the high level of internal
validity found in prospective studies may be compromised
by the application of inappropriate methodologies to data
collection. Particular attention in this workshop is placed
on how validity may be affected by the elapsed time be-
tween admission and reporting, the salience of the treat-
ment event and the perceived social desirability of the
condition. As part of this workshop, we will demonstrate
specific areas where estimates based on patient self-reports
lead to either reliable or suspect values. In particular, we
examine areas of hospitalization, outpatient consultations,
medication use and indirect costs. The impact of patient
self-reports on cost-effectiveness ratios is also discussed.
Attendees of this workshop will gain an understanding of
current methodological shortcomings in this area. Re-
searchers and readers of pharmacoeconomic studies will
gain the skills necessary to better design and evaluate the
validity and potential bias in cost effectiveness analyses.
W19
THE BOOTSTRAP STATISTICAL METHOD FOR 
THE PHARMACOECONOMIC COST ANALYSIS 
OF SKEWED DATA
LeLorier J1, Desgagné A1,2, Castilloux A-M1, Angers J-F1,2
1Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Canada; 2Département de 
mathématiques et de statistique, Université de Montréal, 
Canada
In pharmacoeconomics, the comparison of costs generated
by the use of two different drugs for the same treatment is
of great interest. The problem is especially challenging
when the drugs are likely to produce costly adverse effects
in a small number of patients. The distribution of cost data
is likely to be skewed, and therefore traditional statistical
methods may be inappropriate to analyze the difference in
mean costs. The objective of this workshop is to discuss
the limitations of classical statistical methods used for cost
analysis, and to present an alternative method appropriate
to deal with skewed data. In this workshop, a pharmaco-
economic cost analysis example with skewed data will be
presented. The bootstrap method will be presented as an
alternative approach. Cost analysis will be demonstrated
on an example with classical and alternative methods. The
following statistical methods and their limitations will be
discussed: 1) the Student’s t test, which assumes normality
of data and is sensitive to data skewed for small to moder-
ate sample sizes; 2) the t test on log-transformed data,
which assumes log-normal distributions and equality of
variances of log-transformed data for both samples; and 3)
the nonparametric rank tests, which assumes that the dis-
tributions of data have the same shape and variance. The
bootstrap method will be shown to produce the most reli-
able results for the example given. The use of the nonpara-
metric bootstrap test for most pharmacoeconomic cost
analyses with skewed data and with small to moderate
sample sizes will be discussed. No restricting assumptions
are needed for its application and its ability to deal with
skewing makes it an appropriate alternative.
